InMed Pharmaceuticals Inc. announced the Company has entered into a service contract (the Contract) with Brio Financial Group (Brio) to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3154 USD | +6.95% | +12.68% | -24.18% |
05-14 | Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M | MT |
05-14 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.18% | 1.79M | |
+9.97% | 115B | |
+11.95% | 106B | |
-2.59% | 21.96B | |
-12.41% | 21.87B | |
-5.29% | 19.21B | |
-4.03% | 18.08B | |
-38.57% | 17.71B | |
+7.12% | 14.32B | |
+35.17% | 12.42B |
- Stock Market
- Equities
- INM Stock
- News InMed Pharmaceuticals Inc.
- InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer